GlassScriptPhysician profile
Geoffrey A Rogers
NPI 1265437255
$5,518.50
in general payments reported to CMS, 2019-2025
41 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $231 · 2021: $453 · 2022: $845 · 2023: $1,166 · 2024: $1,214 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.03 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.90 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $572.29 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $517.99 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Abbvie INC. | $457.41 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $451.57 | 2019-2025 | Evenity, Tezspire |
| Pfizer INC. | $411.09 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $305.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $224.09 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $214.19 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.23 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $124.70 | 2023-2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $119.42 | 2019-2023 | Xarelto |
| Ionis Pharmaceuticals, INC. | $116.30 | 2025 | Dawnzera, Donidalorsen |
| Lilly USA, LLC | $112.28 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $96.53 | 2022-2024 | Takhzyro, Cuvitru, Hyqvia |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.